Odyssey Therapeutics (NASDAQ:ODTX) Stock Moved Up to Strong-Buy by UBS Group

UBS Group upgraded shares of Odyssey Therapeutics (NASDAQ:ODTX) to a strong-buy rating in a research note published on Monday morning,Zacks reports.

Several other research firms have also recently issued reports on ODTX. Weiss Ratings started coverage on Odyssey Therapeutics in a research report on Tuesday, August 11th. They set a “sell (d+)” rating for the company. Oppenheimer reissued an “outperform” rating and set a $40.00 target price on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Raymond James Financial started coverage on Odyssey Therapeutics in a research note on Thursday, October 8th. They set an “outperform” rating and a $42.00 target price for the company. Wall Street Zen cut Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Finally, JPMorgan Chase & Co. upped their price target on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Odyssey Therapeutics has an average rating of “Moderate Buy” and an average price target of $35.33.

Odyssey Therapeutics Trading Down 5.6%

Shares of ODTX stock opened at $17.24 on Monday. The firm has a market capitalization of $828.55 million and a P/E ratio of -2.55. The stock’s fifty day moving average price is $22.71. Odyssey Therapeutics has a 12 month low of $15.10 and a 12 month high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. As a group, equities analysts expect that Odyssey Therapeutics will post -6.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Odyssey Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ODTX. Citadel Advisors LLC acquired a new position in Odyssey Therapeutics in the second quarter valued at $4,162,000. State Street Corp purchased a new position in shares of Odyssey Therapeutics during the second quarter worth about $1,477,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Odyssey Therapeutics during the second quarter worth about $601,000.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.